Design, development and clinical translation of Cripec®-based core-crosslinked polymeric micelles
…, RMJ Liskamp, RHJ Mathijssen, IHC Miedema… - Advanced drug delivery …, 2022 - Elsevier
Nanomedicines are used to improve the efficacy and safety of pharmacotherapeutic
interventions. Unraveling the biological behavior of nanomedicines, including their biodistribution …
interventions. Unraveling the biological behavior of nanomedicines, including their biodistribution …
PET‐CT Imaging of Polymeric Nanoparticle Tumor Accumulation in Patients
IHC Miedema, GJC Zwezerijnen… - Advanced …, 2022 - Wiley Online Library
Several FDA/EMA‐approved nanomedicines have demonstrated improved pharmacokinetics
and toxicity profiles compared to their conventional chemotherapeutic counterparts. The …
and toxicity profiles compared to their conventional chemotherapeutic counterparts. The …
[HTML][HTML] 89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC
IHC Miedema, MC Huisman, GJC Zwezerijnen… - European journal of …, 2023 - Springer
Purpose Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate
promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive …
promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive …
89Zr-DFO-Durvalumab PET/CT before durvalumab treatment in patients with recurrent or metastatic head and neck cancer
…, SF Oosting, AH Brouwers, IHC Miedema… - Journal of Nuclear …, 2022 - Soc Nuclear Med
In this PD-L1 ImagiNg to prediCt durvalumab treatment response in SCCHN (PINCH) study,
we performed 89 Zr-DFO-durvalumab (anti–PD-L1 [programmed death ligand 1]) PET/CT in …
we performed 89 Zr-DFO-durvalumab (anti–PD-L1 [programmed death ligand 1]) PET/CT in …
Praluzatamab ravtansine, a CD166-targeting antibody–drug conjugate, in patients with advanced solid tumors: an open-label phase I/II trial
…, S Jalal, JJ Harding, SK Kim, IHC Miedema… - Clinical Cancer …, 2022 - AACR
… Iris HC Miedema … Iris HC Miedema … Kim, Iris HC Miedema, Danielle J. Vugts, Marc C.
Huisman, Gerben JC Zwezerijnen, Guus AMS van Dongen, C. …
Huisman, Gerben JC Zwezerijnen, Guus AMS van Dongen, C. …
[HTML][HTML] 89Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs
IHC Miedema, JE Wijngaarden, JEE Pouw… - Cancers, 2023 - mdpi.com
Simple Summary The uptake on a 89 Zr-immuno-PET scan is not just the result of the
binding of a radiolabeled antibody with its target (ie, target engagement) but also includes …
binding of a radiolabeled antibody with its target (ie, target engagement) but also includes …
Multiparameter flow cytometry assay for quantification of immune cell subsets, PD‐1 expression levels and PD‐1 receptor occupancy by nivolumab and …
D Pluim, W Ros, IHC Miedema, JH Beijnen… - Cytometry Part …, 2019 - Wiley Online Library
We report the development and validation of a 12 parameter immunofluorescence flow
cytometry method for the sensitive determination of cell concentrations, their expression of PD‐1, …
cytometry method for the sensitive determination of cell concentrations, their expression of PD‐1, …
First-in-human imaging of nanoparticle entrapped docetaxel (CPC634) in patients with advanced solid tumors using 89Zr-Df-CPC634 PET/CT.
IHC Miedema, GJC Zwezerijnen, DE Oprea-Lager… - 2019 - ascopubs.org
3093 Background: CPC634 is a nanoparticle entrapping docetaxel designed to improve
tumor accumulation and tolerability compared to conventionally administered docetaxel by …
tumor accumulation and tolerability compared to conventionally administered docetaxel by …
Localized peritumoral AL amyloidosis associated with mantle cell lymphoma with plasmacytic differentiation
…, MS Ritorto, E Barbé, IHC Miedema… - The American journal …, 2021 - journals.lww.com
Immunoglobulin light chain (AL) amyloidosis is characterized by the deposition of amyloid
fibers derived from pathologic immunoglobulin light chains. Although systemic plasma cell …
fibers derived from pathologic immunoglobulin light chains. Although systemic plasma cell …
[HTML][HTML] Abundance of Early Functional HIV-Specific CD8+ T Cells Does Not Predict AIDS-Free Survival Time
…, IM De Cuyper, RB Geskus, D van Baarle, F Miedema - PLoS …, 2008 - journals.plos.org
Background T-cell immunity is thought to play an important role in controlling HIV infection,
and is a main target for HIV vaccine development. HIV-specific central memory CD8 + and …
and is a main target for HIV vaccine development. HIV-specific central memory CD8 + and …